ALPHA BIOLOGICS SECURES FURTHER $3 MILLION
IN LATEST FUNDING ROUND

20 November 2006

Alpha Biologics Sdn Bhd, the UK and Malaysian-based contract manufacturer of biologics drugs, is pleased to announce that it has successfully raised $3 million through its latest funding round.

The capital, all of which has come from Pequot Capital Management, Inc, in the US, will help support current commercial discussions and the on-going construction of the company’s $18 million, 5,000 sq metre manufacturing facility in Penang.

With $3 million already raised earlier this year, this latest funding round brings the total raised by Alpha Biologics in 2006 to $6 million. The company’s main investors now include SpringHill BioVentures Sdn Bhd, Asiaprise Biotech Sdn.Bhd and Pequot.

The completion of the latest funding round coincides with the official visit by Tan Sri Dr Koh Tsu Koon on 20 November to view Alpha Biologics’ soon to be completed facility on the Penang Biotech Park.

Established in 2003 with the support of the Penang Development Corporation (PDC) and Malaysian Industrial Development Authority (MIDA), Alpha Biologics is set to become one of the leading players in Malaysia’s emerging life sciences industry. The company will provide biopharma and pharma companies with the opportunity to take biologic drugs through pre-clinical, phase 1 and phase 2 trials with a strong emphasis on cost efficiency. Alpha Biologics will specialise in the production of mammalian cell secreted protein drugs, providing all of the necessary services required to develop and produce drugs in full compliance with US and European cGMP guidelines.

Construction of the facility’s external shell was finished in October 2006 with clean room installation due to commence in November. The facility is scheduled for completion with all bioprocess equipment installed mid-2007. Further validation and qualification will continue with the facility becoming fully operational by the end of 2007.

Commenting on the latest successful funding round, Simon Saxby, Chief Executive at Alpha Biologics, said: “I am especially pleased to welcome such a high quality investor to the company. Pequot has considerable presence in worldwide life science investments. This is a particularly significant move for Alpha Biologics. It provides us with additional financial security as we draw towards the end of the construction phase of the Penang facility.”

Back to News